- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06292169
Libération mineure du pectoral et non-libération dans RSA
Un essai contrôlé randomisé pour évaluer la libération par rapport à la non-libération du petit pectoral avec arthroplastie inversée de l'épaule
The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are:
- whether releasing the pectoralis minor prophylactically could have better pain relief
- whether releasing the pectoralis minor prophylactically could have increased Range of motion (ROM) outcomes
- whether releasing the pectoralis minor prophylactically could have higher final Patient Reported Outcome Measurements (PROMs) Participants will be randomized to either undergo RSA with pectoralis minor release or RSA without pectoralis minor release.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Shoulder arthroplasty has been increasing at exponential rates, particularly due to the rise of reverse shoulder arthroplasty (RSA). Postoperative complications after RSA include infection, instability, hardware component loosening, acromial and scapular spine fractures, neurologic injury, and scapular notching which can all cause pain. However, despite excluding these causes, some patients can have persistent anterior shoulder pain with poor motion.
RSA prostheses work by translating the center of rotation (COR) inferiorly and medially, which increases tension on the deltoid, which is thought to increase the deltoid's mechanical moment arm and thus its ability to abduct and flex the humerus. However, excessive lengthening may be a cause of acromial and scapular spine fractures or neurologic injury. In addition, other structures are tensioned, including the conjoint tendon (short head of the biceps brachii and coracobrachialis) and pec minor (PM). It is unclear if lengthening these muscle-tendon units has functional consequences or whether it can create an intrinsic pathology. It is therefore feasible that muscle lengthening could create tendinitis, which could lead to persistent anterior shoulder pain after RSA. In addition, excessive tension or over-activity in the PM is also known to be a cause of altered scapula biomechanics.
Good scapula biomechanics after RSA are critical to preserving an impingement-free range of motion, which is important in maximizing postoperative outcomes, implant longevity, and preventing component loosening and instability. However, it is known from the non-arthroplasty population that during repetitive movements with scapular protraction, a hyperactive or spasming PM shortens and develops contracture, leading to protracted resting scapular position and altered scapular contribution to shoulder range of motion.1 This causes altered scapular kinematics, or dyskinesia, and alters scapular accommodation to shoulder motion, a well-known feature in various shoulder pathologies. This can be a major problem after RSA when scapula accommodation is critical to ROM and function.
Due to the expendability of the pectoralis minor, its release would cause minimal functional detriment in non-pathological cases, but in cases of overactivity, release could markedly improve scapula biomechanics. This can be performed open or arthroscopically, but the concomitant open release would be straight-forward at the time of the index surgery through the same incision
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory Clinic
-
Atlanta, Georgia, États-Unis, 30329
- Emory Healthcare Orthopaedics and Spine Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- All patients undergoing surgery for reverse total shoulder arthroplasty
- Patients willing and able to provide informed consent
Exclusion Criteria:
- Revision arthroplasty
- Reverse shoulder arthroplasty for proximal humerus fractures
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RSA avec libération mineure du pectoral
|
The pectoralis minor is a muscle on the anterior chest wall attaching to the coracoid process. In the group undergoing pectoralis minor release, through the same deltopectoral incision that will not be extended or different as compared to the RSA only group, the pec minor will be exposed on the medial aspect of the coracoid at the upper part of the incision. It will be cut from its insertion on the coracoid while being careful to protect any neurovascular structures. RSA is the current Standard of Care (SOC) |
|
Comparateur actif: RSA sans libération mineure du pectoral
|
RSA is the current Standard of Care (SOC) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visual analog Scale (VAS) pain scores
Délai: Baseline, 6 months
|
The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line |
Baseline, 6 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Visual analog Scale (VAS) pain scores
Délai: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Study participants will be asked to rate their current level of pain by placing a mark on the line |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
American Shoulder and Elbow Score (ASES)
Délai: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
The ASES is a 100-point scale that consists of two dimensions: pain and activities of daily living. There is one pain scale worth 50 points and ten activities of daily living worth 50 points. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Subjective Shoulder Value (SSV)
Délai: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
Subjective Shoulder Value is study participant's subjective shoulder assessment expressed as a percentage of an entirely normal shoulder, which would score 100% |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Change in Range of motion (ROM)
Délai: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
ROM is calculated in terms of angles. Lower number suggests restricted motion. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Change in Scapulohumeral Rhythm (SHR) on Digital Dynamic Radiography (DDR)
Délai: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
SHR is the ratio of humeral abduction over the change in scapula upward rotation during humeral abduction. This SHR will be captured on Digital Dynamic Radiography (DDR) and reported as a change in SHR before and after the interventions. |
Baseline, 2 weeks, 6 weeks, 3 months, 6 months, 1 year (each follow-up visit)
|
|
Number of complications
Délai: 1 year
|
Number of complications post intervention would be measured. |
1 year
|
|
Number of reoperations
Délai: 1 year
|
Number of reoperations following intervention would be measured. |
1 year
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Eric Wagner, MD, Emory University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00007201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .